Shin Kaneko
Overview
Explore the profile of Shin Kaneko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1710
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mishima Y, Okada S, Ishikawa A, Wang B, Waseda M, Kaneko M, et al.
Regen Ther
. 2025 Jan;
28:292-300.
PMID: 39867135
Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of CD19-positive B-cell malignancies. However, the field is rapidly evolving to target other antigens, such as podocalyxin (PODXL), a transmembrane...
2.
Shin S, Mishima Y, Lee Y, Kwon O, Kim J, Kim Y, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39865534
Adoptive cell therapy (ACT) is a type of immunotherapy in which autologous or allogeneic immune cells, such as tumor-infiltrating lymphocytes or engineered lymphocytes, are infused into patients with cancer to...
3.
Yano H, Koga K, Sato T, Shinohara T, Iriguchi S, Matsuda A, et al.
Cell Stem Cell
. 2024 Jun;
31(6):795-802.e6.
PMID: 38848686
CD4 T cells induced from human iPSCs (iCD4 T cells) offer a therapeutic opportunity for overcoming immune pathologies arising from hematopoietic stem cell transplantation. However, most iCD4 T cells are...
4.
Takayanagi S, Chuganji S, Tanaka M, Wang B, Hasegawa S, Fukumoto K, et al.
Commun Biol
. 2024 Jun;
7(1):685.
PMID: 38834758
Memory T cells demonstrate superior in vivo persistence and antitumor efficacy. However, methods for manufacturing less differentiated T cells are not yet well-established. Here, we show that producing chimeric antigen...
5.
Kurihara S, Ishikawa A, Kaneko S
Inflamm Regen
. 2024 Apr;
44(1):20.
PMID: 38637837
In recent years, immunotherapy has become a standard cancer therapy, joining surgery, chemotherapy, and radiation therapy. This therapeutic approach involves the use of patient-derived antigen-specific T cells or genetically modified...
6.
Tanaka M, Iwamoto Y, Wang B, Imai E, Yoshida M, Iriguchi S, et al.
Regen Ther
. 2024 Mar;
27:104-111.
PMID: 38545443
Introduction: Genetically modified human induced pluripotent stem cell (iPSC)-based regenerative medicine has substantial potential in the treatment of refractory human diseases. Thus, preclinical studies on the safety and efficacy of...
7.
Ishiguro Y, Iriguchi S, Asano S, Shinohara T, Shiina S, Arima S, et al.
Front Immunol
. 2024 Jan;
14:1303713.
PMID: 38162650
Introduction: T cells induced from induced pluripotent stem cells(iPSCs) derived from antigen-specific T cells (T-iPS-T cells) are an attractive tool for T cell immunotherapy. The induction of cytotoxic T-iPS-T cells...
8.
Gravina A, Tediashvili G, Zheng Y, Iwabuchi K, Peyrot S, Roodsari S, et al.
Cell Stem Cell
. 2023 Nov;
30(11):1538-1548.e4.
PMID: 37922880
Immune rejection of allogeneic cell therapeutics remains a major problem for immuno-oncology and regenerative medicine. Allogeneic cell products so far have inferior persistence and efficacy when compared with autologous alternatives....
9.
Bae J, Kitayama S, Herbert Z, Daheron L, Kurata K, Keskin D, et al.
Blood
. 2023 Oct;
143(10):895-911.
PMID: 37890146
A major hurdle in adoptive T-cell therapy is cell exhaustion and failure to maintain antitumor responses. Here, we introduce an induced pluripotent stem cell (iPSC) strategy for reprogramming and revitalizing...
10.
Takayanagi S, Wang B, Hasegawa S, Nishikawa S, Fukumoto K, Nakano K, et al.
Mol Ther Methods Clin Dev
. 2023 Oct;
31:101109.
PMID: 37822720
Allogeneic T cell platforms utilizing induced pluripotent stem cell (iPSC) technology exhibit significant promise for the facilitation of adoptive immunotherapies. While mature T cell receptor (TCR) signaling plays a crucial...